Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554466 | 0.87 | KLKB1 (0.49) | KLKB1FAAHCES1RIPK1 | |
| SCHEMBL553924 | 0.78 | KLKB1 (0.48) | KLKB1RIPK1 | |
| SCHEMBL234833 | 0.74 | AOC3 (0.44) | KLKB1 | |
| SCHEMBL23337234 | 0.73 | FAAH (0.52) | FAAHCES1PLA2G10PLA2G2A | |
| SCHEMBL756483 | 0.73 | P4HTM (0.41) | KLKB1FAAHRIPK1 | |
| SCHEMBL22262722 | 0.73 | KLKB1 (0.48) | KLKB1 | |
| SCHEMBL4150589 | 0.73 | PLA2G10 (0.56) | PLA2G10PLA2G2A | |
| SCHEMBL5210936 | 0.72 | CES1 (0.48) | FAAHCES1 | |
| SCHEMBL3826537 | 0.72 | RAB9A (0.51) | KLKB1PLA2G10PLA2G2A | |
| SCHEMBL2854984 | 0.71 | KDM4E (0.60) | FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234810-A | Cell apoptosis inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2023-06-06 | — | — | CN | disclosed |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-114262322-A | Apoptosis inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2022-04-01 | — | — | CN | disclosed |
| EP-3816163-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | KLKB1 3282/4885FAAH 1084/4885CES1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.